Abstract
Since its emergence in September 2012, about half of the individuals known to be infected with Middle East respiratory syndrome coronavirus (MERS-CoV) have died. There is currently no treatment for MERS-CoV infection but interferon alfa-2b and ribavirin reduce viral replication in vitro. Now, researchers report that early treatment with this combination of drugs, which is already used clinically to treat other viral infections, reduces viral replication, moderates the host immune response, and improves outcomes in rhesus macaques infected with MERS-CoV, an animal model for mild-to-moderate MERS-CoV infection.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
